[New therapeutic regimes in metastasic renal-cell carcinoma].

作者信息

Bierer S, Hertle L, Nitschmann S

机构信息

Klinik und Poliklinik für Urologie, Universitätsklinikum Münster, Albert-Schweitzer-Strasse 33, 48149, Münster, Deutschland.

出版信息

Internist (Berl). 2008 Jan;49(1):114-7. doi: 10.1007/s00108-007-1972-0.

DOI:10.1007/s00108-007-1972-0

PMID:18704353

Abstract

摘要

相似文献

[New therapeutic regimes in metastasic renal-cell carcinoma].

Internist (Berl). 2008 Jan;49(1):114-7. doi: 10.1007/s00108-007-1972-0.

Therapy for metastatic RCC--questions remain.

Nat Rev Urol. 2009 Nov;6(11):580-1. doi: 10.1038/nrurol.2009.210.

CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.

Clin Cancer Res. 2007 Jul 1;13(13):3765-70. doi: 10.1158/1078-0432.CCR-06-2844.

Health policy: The UK 'postcode lottery' in renal cell carcinoma.

Nat Rev Urol. 2009 Dec;6(12):636-8. doi: 10.1038/nrurol.2009.228.

Kidney cancer: Does hypothyroidism predict clinical outcome?

Nat Rev Urol. 2011 Jan;8(1):10-1. doi: 10.1038/nrurol.2010.191. Epub 2010 Nov 30.

The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.

Acta Oncol. 2009;48(6):927-31. doi: 10.1080/02841860902974167.

Editorial comment.

Urology. 2010 May;75(5):1114-5; author reply 1115. doi: 10.1016/j.urology.2009.07.1291.

Editorial comment.

Urology. 2010 May;75(5):1114; author reply 1115. doi: 10.1016/j.urology.2009.07.1290.

Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.

Clin Genitourin Cancer. 2006 Jun;5(1):78-81. doi: 10.3816/CGC.2006.n.021.

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.

J Urol. 2008 Jan;179(1):81-6; discussion 86. doi: 10.1016/j.juro.2007.08.127. Epub 2007 Nov 12.

本文引用的文献

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

N Engl J Med. 2007 May 31;356(22):2271-81. doi: 10.1056/NEJMoa066838.

Immunotherapy for advanced renal cell cancer.

Cochrane Database Syst Rev. 2005 Jan 25(1):CD001425. doi: 10.1002/14651858.CD001425.pub2.

Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy.

J Clin Oncol. 1996 Aug;14(8):2410-1. doi: 10.1200/JCO.1996.14.8.2410.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

[New therapeutic regimes in metastasic renal-cell carcinoma].

Internist (Berl). 2008 Jan;49(1):114-7. doi: 10.1007/s00108-007-1972-0.

Therapy for metastatic RCC--questions remain.

Nat Rev Urol. 2009 Nov;6(11):580-1. doi: 10.1038/nrurol.2009.210.

CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.

Clin Cancer Res. 2007 Jul 1;13(13):3765-70. doi: 10.1158/1078-0432.CCR-06-2844.

Health policy: The UK 'postcode lottery' in renal cell carcinoma.

Nat Rev Urol. 2009 Dec;6(12):636-8. doi: 10.1038/nrurol.2009.228.

Kidney cancer: Does hypothyroidism predict clinical outcome?

Nat Rev Urol. 2011 Jan;8(1):10-1. doi: 10.1038/nrurol.2010.191. Epub 2010 Nov 30.

The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.

Acta Oncol. 2009;48(6):927-31. doi: 10.1080/02841860902974167.

Editorial comment.

Urology. 2010 May;75(5):1114-5; author reply 1115. doi: 10.1016/j.urology.2009.07.1291.

Editorial comment.

Urology. 2010 May;75(5):1114; author reply 1115. doi: 10.1016/j.urology.2009.07.1290.

Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.

Clin Genitourin Cancer. 2006 Jun;5(1):78-81. doi: 10.3816/CGC.2006.n.021.

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.

J Urol. 2008 Jan;179(1):81-6; discussion 86. doi: 10.1016/j.juro.2007.08.127. Epub 2007 Nov 12.

本文引用的文献

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

N Engl J Med. 2007 May 31;356(22):2271-81. doi: 10.1056/NEJMoa066838.

Immunotherapy for advanced renal cell cancer.

Cochrane Database Syst Rev. 2005 Jan 25(1):CD001425. doi: 10.1002/14651858.CD001425.pub2.

Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy.

J Clin Oncol. 1996 Aug;14(8):2410-1. doi: 10.1200/JCO.1996.14.8.2410.